Tesofensine and alcohol addiction: separating signal from TikTok hype

What did @thesanctuarysd actually say?

The creator describes using a compound they call "Casophansi" (almost certainly tesofensine, a real investigational drug) to stop drinking roughly five days a week, including a period where they could "drink a bottle of wine in an hour and blow a zero on a breathalyzer." They call it a "triple agonist of norepinephrine, serotonin, and dopamine" that will "stop addiction for sure." After quitting alcohol, they added three peptides, Selank, Semax, and Dihexa, claiming their brain returned to how it felt at age 20 within a couple of months.

The caption labels tesofensine a GLP-1 drug, which it is not. That alone signals there is some confusion, either from the creator or whoever wrote the caption, about what this compound actually does. The core claim here is that a research-stage drug stopped alcohol dependency and that peptide stacking repaired a decade of alcohol-related brain damage. Those are serious claims that deserve serious scrutiny.

Does the science back this up?

Tesofensine's mechanism is real. The addiction angle has some biological plausibility. The "brain back to age 20" claim does not have meaningful clinical support.

Tesofensine is a triple monoamine reuptake inhibitor, blocking reuptake of norepinephrine, dopamine, and serotonin. It was originally developed by Neurosearch for Parkinson's and Alzheimer's. Phase 2 trials were halted for those indications largely because of cardiovascular side effects and unexpected weight loss, which then became its primary research focus. Astrup et al. (2008, Lancet) showed significant weight loss in a 24-week trial, which is why obesity researchers picked it up.

On alcohol: dopamine and serotonin systems are deeply involved in alcohol use disorder. Drugs that modulate those systems, like naltrexone and acamprosate, are FDA-approved for that reason. There is no published clinical trial showing tesofensine reduces alcohol use in humans. The "triple agonist" label the creator uses is also wrong. Tesofensine is a reuptake inhibitor, not an agonist. It prevents reabsorption of those neurotransmitters rather than directly activating receptors. For a non-specialist audience, that distinction matters.

The peptides (Selank, Semax, Dihexa) have preliminary animal data or small human studies, mostly from Russian research groups, but none have completed rigorous Phase 3 trials demonstrating neuroregeneration in humans recovering from alcohol use disorder.

What did they get wrong (or right)?

They got the drug's history roughly right. Mostly wrong on the mechanism and made an unsupported leap on addiction.

Credit where it is due: the creator accurately described that tesofensine went through Phase 2 trials for neurological diseases and that those trials were stopped partly because of dramatic weight loss as an adverse event. That matches the published record. Astrup's 2008 Lancet data confirmed this. The creator also made an important personal admission that they "knew it was doing harm," which is a more honest self-assessment than most substance-use content on TikTok offers.

But calling tesofensine a "triple agonist" is incorrect. It is a reuptake inhibitor. The pharmacological distinction is not pedantic: agonists activate receptors directly, reuptake inhibitors work upstream. Saying it will "stop addiction for sure" is irresponsible, full stop. There is no clinical evidence supporting that claim for this specific compound in humans with alcohol use disorder. And the claim that Semax, Selank, and Dihexa repaired a decade of alcohol-related neurological damage within two months is not supported by any peer-reviewed human trial data we are aware of.

What should you actually know?

Tesofensine is not approved anywhere for alcohol use disorder. Self-medicating with it carries real cardiovascular risk. There are actual approved treatments for alcohol dependency.

Tesofensine's most consistent adverse effects in trials included increased heart rate and blood pressure. Godoy-Matos et al. (2021, Drugs) reviewed the cardiovascular signal and noted it remains a reason the drug has not cleared regulatory approval despite promising weight-loss data. Someone with a history of heavy alcohol use, who may already have elevated cardiovascular risk, self-administering an unapproved compound with a known heart rate elevation profile is not a neutral decision.

FDA-approved medications for alcohol use disorder include naltrexone, acamprosate, and disulfiram. Naltrexone in particular has a well-documented mechanism and evidence base for reducing craving and relapse. GLP-1 receptor agonists like semaglutide are also showing early promise in alcohol reduction, with Klausen et al. (2022, JCI Insight) showing reduced alcohol intake in animal models and early human signals emerging. None of this means tesofensine has zero future in this space, but a TikTok video is not a clinical trial.

If alcohol use is affecting your health, a regulated telehealth provider can evaluate whether approved pharmacotherapy is appropriate for you. Ordering unapproved compounds from research chemical suppliers based on a social media video is a different category of decision entirely.